Aclarion Partners with Weill Cornell Medicine to Study Nociscan in Spine Treatments — Aclarion, Inc.

Event summary

Aclarion has signed a commercial agreement with Weill Cornell Medicine to integrate its Nociscan platform into a clinical trial studying stem cell treatments for degenerative disc disease.
The trial, led by Dr. Jaspal Ricky Singh, will evaluate the efficacy of bone marrow aspirate stem cell concentrate (BMAC) in treating chronic low back pain (cLBP).
Nociscan will be used to identify painful discs in a subset of patients, providing objective biomarker data to guide treatment decisions.
The study is part of a broader effort to address the 266 million people worldwide suffering from degenerative spine disease and low back pain.

The big picture

Aclarion’s collaboration with Weill Cornell Medicine marks a strategic step toward validating its Nociscan platform in a high-profile clinical setting. The partnership leverages Aclarion’s AI-driven diagnostics in a field where chronic low back pain remains a significant unmet medical need. Success in this trial could position Nociscan as a key tool in precision spine care, potentially expanding its role in both diagnostic and treatment planning.

What we're watching

Clinical Validation: Whether Nociscan’s biomarker data can demonstrate a clear link between disc pain and treatment outcomes in this trial.
Market Expansion: The pace at which Aclarion can secure additional partnerships with leading medical institutions to broaden Nociscan’s adoption.
Regulatory Pathway: How the results of this trial may influence future regulatory approvals or reimbursement policies for Nociscan.